Tumor mutational burden is associated with poor outcomes in diffuse glioma | BMC Cancer | Full Text

Tumor mutational burden is associated with poor outcomes in diffuse glioma | BMC Cancer | Full Text

Tumor mutational burden is associated with poor outcomes in diffuse glioma

Tumor mutational burden (TMB) is a potential biomarker for immune checkpoint therapy and prognosis. The impact of TMB on clinical outcomes and the correlation coefficient between exome sequencing and targeted ...

Authors:Lihong Wang, Jia Ge, Yang Lan, Yu Shi, Ying Luo, Yuhuan Tan, Mei Liang, Song Deng, Xia Zhang, Wenying Wang, Yaoyao Tan, Yuanyuan Xu and Tao Luo

Citation:BMC Cancer 2020 20:213

Content type:Research article

Published on: 12 March 2020

• ViewFull Text
 
• ViewPDF